Buccal delivery of glucagon-like insulinotropic peptides
US5766620A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Oct 23, 1995 |
| Grant date | Jun 16, 1998 |
| Priority date | — |
| Expiry date | Oct 23, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Drug delivery systems and methods for administering a glucagon-like insulinotropic peptide to the buccal mucosa for transmucosal drug delivery are described. The drug delivery systems comprise a drug composition containing an effective amount of the glucagon-like insulinotropic peptide and an effective amount of a permeation enhancer for enhancing permeation of glucagon-like insulinotropic peptide through the buccal mucosa and means for maintaining the drug composition in a drug transferring relationship with with buccal mucosa. These systems can be in free form, such as creams, gels, and ointments, or can comprise a device of determined physical form, such as tablets, patches, and troches. A preferred glucagon-like insulinotropic peptide is GLP-1(7-36)amide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.